Evidence map›Paper›PMID 40213940›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Assessment and Mitigation of CRISPR-Cas9-Induced Nontargeted Translocations.

Zhiyang Hou, Qiyi Yi, Mengying Wu, Lijun Wu, Fanghua Li, Ting Wang, Po Bian

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Assessment and Mitigation of CRISPR-Cas9-Induced Nontargeted Translocations.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhiyang HouSchool of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, China.
Qiyi YiSchool of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, China.
Mengying WuSchool of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, China.
Lijun WuInstitute of Physical Science and Information Technology, Anhui University, Hefei, 230601, China.
Fanghua LiDepartment of Particle Therapy, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), German Cancer Consortium (DKTK), University Hospital Essen, 45147, Essen, Germany.
Ting WangSchool of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, China.
Po BianSchool of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, China.ORCID https://orcid.org/0000-0002-2581-9317

Funding

National Natural Science Foundation of China 12075275National Natural Science Foundation of China 12135016National Natural Science Foundation of China 12475335Space Medical Experiment Project of China Manned Space Program HYZHXMH02002
6 · The paper itself

Abstract

The performance of CRISPR-mediated genome editing near inverted repeats (IRs) potentially results in chromosomal translocations and other catastrophic rearrangements. However, the extent of this risk may be significantly underestimated because current reporter systems focus solely on site-specific translocations. Here, trans-acting reporter systems in Escherichia coli are developed to detect nontargeted translocations. Markedly increased frequency of translocations following CRISPR-Cas9 activation is observed, with the magnitude determined primarily by the length of the IRs and the proximity between Cas9 target sites and IRs. These translocations arise through a combination of intramolecular single-strand annealing and alternative end-joining mechanisms. Furthermore, it is discovered that introducing segments homologous to IR loci can substantially mitigate nontargeted translocations without significantly compromising CRISPR-Cas9-mediated editing. The study provides valuable insights into the genetic risks associated with CRISPR technologies and suggests a viable strategy for developing genetically safer CRISPR systems.

Indexed as

CRISPR-Cas SystemsGene EditingTranslocation, GeneticEscherichia colialternative end‐joiningchromosomal rearrangementCRISPR‐mediated genome editingDNA single‐strand annealingnontargeted translocation

Identifiers

PMID40213940
PMCPMC12140377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.